As the COVID-19 pandemic continues, many cancer patients are having to make the difficult decision to continue with their current cancer regimen or delay treatments. Cancer patients and physicians must carefully weigh the potential benefit of routine cancer care versus the risk of COVID-19. To help ease these decisions, several peer-reviewed, non-profit cancer care organizations […]
When deciding which treatment option is best for their prostate cancer, men take numerous factors into consideration. While their physician’s recommendation does play an important role in the treatment decision, in the end, most men make the choice that is best for them. That choice is often based on treatment outcomes and side effects, and […]
Accuray Incorporated, developer and manufacturer of the CyberKnife® System, announced that published data from two multicenter studies using differing protocols provide consistent results and reinforce the use of the CyberKnife system for the effective management of low-and intermediate-risk prostate cancer. The studies are the largest conducted to date evaluating stereotactic body radiation therapy (SBRT) in […]
Accuray, the company that develops and manufactures the CyberKnife® Robotic Radiosurgery System, the system that New Jersey CyberKnife uses to treat cancer, recently announced the results of the first study that evaluated the use of stereotactic body radiation therapy (SBRT) in low-risk prostate cancer 10 years post treatment. The study titled, “Stereotactic Body Radiotherapy for […]
Last week, the American Urological Association (AUA), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) released collaborative clinical guidelines for managing localized prostate cancer which offers a framework for shared decision-making between physicians and patients. Through this collaboration, the committee provided guidance on active surveillance and on which treatments […]
According to research presented at the recent 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), high dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates. The Cyberknife at New Jersey Cyberknife delivers SBRT. Although […]
A recent study found that mid-life prostate-specific antigen (PSA) levels predict who will be more likely to develop lethal prostate cancer. Investigators from Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health found that measuring PSA levels in younger men (between the ages of 40 and 59) could accurately predict future […]
According to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, a five-year study shows that stereotactic body radiation therapy (SBRT), which can be administered with the CyberKnife® Robotic Radiosurgery System, offers a higher cure rate for prostate cancer than more traditional approaches. The study, the first trial to publish five-year results […]
